替吉奥联合阿帕替尼对化疗失败晚期胃癌患者的临床疗效分析  

Analysis of clinical efficacy of tegafur combined with apatinib in patients with advanced gastric cancer after chemotherapy failure

作　　者：孙折玉 徐燕[2] 梁妍娇 姚娟[3] Sun Zheyu;XU Yan;LIANG Yanjiao;YAO Juan(Department of Radiotherapy Second Branch,Affiliated Qingdao Central Hospital of Qingdao University,Qingdao Shandong 266042 China;Department Of Stereotactic Radiotherapy,Affiliated Qingdao Central Hospital of Qingdao University,Qingdao Shandong 266042 China;Western and Chinese Medicine,Affiliated Qingdao Central Hospital of Qingdao University,Qingdao Shandong 266042 China)

机构地区：[1]青岛大学附属青岛市中心医院放射治疗二科,山东青岛266042 [2]青岛大学附属青岛市中心医院肿瘤立体定向放疗科,山东青岛266042 [3]青岛大学附属青岛市中心医院中西医科,山东青岛266042

出　　处：《中国临床医生杂志》2021年第9期1033-1036,共4页Chinese Journal For Clinicians

基　　金：山东省青岛市科技委员会进步奖项支持项目(J2020-2-70-5)。

摘　　要：目的分析化疗失败晚期胃癌患者替吉奥联合阿帕替尼治疗的临床疗效。方法回顾性选取2017年10月至2019年10月青岛大学附属青岛市中心医院化疗失败晚期胃癌患者100例,依据治疗方法分为替吉奥联合阿帕替尼治疗组(联合治疗组)、替吉奥单药治疗组(单一治疗组),每组各50例,统计分析两组患者的临床疗效、不良反应发生情况、生存情况。结果联合治疗组患者疾病控制率90.0%(45/50)显著高于单药治疗组78.0%(39/50)(P<0.05)。联合治疗组患者的高血压、口腔黏膜炎、白细胞减少发生率均显著高于单药治疗组(P<0.05),但两组患者的恶心呕吐、乏力、手足综合征、血小板减少、血红蛋白下降、蛋白尿发生率之间的差异无显著性(P>0.05)。联合治疗组患者的无进展生存期、总生存期均显著长于单药治疗组(P<0.05)。结论化疗失败晚期胃癌患者替吉奥联合阿帕替尼治疗的临床疗效优于替吉奥单独治疗。Objective To analyze the clinical efficacy of tegafur combined with apatinib in the treatment of advanced gastric cancer patients with chemotherapy failure.Methods 100 cases of advanced gastric cancer patients with chemotherapy failure in our hospital from October 2017 to October 2019 were selected retrospectively.According to the treatment methods,they were divided into two groups:S-1 combined with apatinib treatment group(combined treatment group)and S-1 alone treatment group(single treatment group),with 50 cases in each group.The clinical efficacy,adverse reactions and survivals of the two groups were statistically analyzed.Results The disease control rate of the combined treatment group was 90.0%(45/50),which was significantly higher than 78.0%(39/50)of the single treatment group(P<0.05).The incidences of diarrhea,oral mucositis and leucopenia in the combined treatment group were significantly higher than the single treatment group(P<0.05),but the differences of incidences of nausea and vomiting,fatigue,hand foot syndrome,thrombocytopenia,decreased hemoglobin and proteinuria between the two groups were not significant(P>0.05).The progression free survival and overall survival of the combined treatment group were significantly longer than the single treatment group(P<0.05).Conclusion The clinical efficacy of tegafur combined with apatinib in the treatment of advanced gastric cancer patients with chemotherapy failure was better than tegafur alone.

关 键 词：化疗失败 晚期胃癌 替吉奥 阿帕替尼 不良反应 生存情况 

分 类 号：R735.3[医药卫生—肿瘤]